drugset / Trial / NCT01017770
Artemether-lumefantrine (AL) Versus Artesunate + Amodiaquine (ASAQ) for the Treatment of Uncomplicated Falciparum Malaria in Burkina Faso
RandomizedParallel-groupOpen-labelTreatment
Summary
Several countries in Africa have changed their first-line treatment for uncomplicated malaria to an ACT. Burkina Faso has changed its policy to Artemether-Lumefantrine (AL) and Artesunate-Amodiaquine (AQ+AS). However, such choice has been done without knowing the local effectiveness of these drugs when they are given to patients in real life conditions, without direct observation of the drug administration. Thus, this study aims at investigating the effectiveness of AQ+AS and AL, when given to children with uncomplicated malaria in Burkina Faso.
Timeline
- Start
- 2008-09
- Primary completion
- 2010-01
- Completion
- 2010-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Artemether-lumefantrine | Unknown | — | — |
| Subject | Artesunate-amodiaquine | Unknown | 25 mg | — |
| Subject | Artesunate-amodiaquine | Unknown | 50 mg | — |
| Subject | Artesunate-amodiaquine | Unknown | 67.5 mg | — |
| Subject | Artesunate-amodiaquine | Unknown | 100 mg | — |
| Subject | Artesunate-amodiaquine | Unknown | 135 mg | — |
| Subject | Artesunate-amodiaquine | Unknown | 270 mg | — |